ST 36

Drug Profile

ST 36

Alternative Names: ST-36

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Columbia University
  • Developer Sapience Therapeutics
  • Class Peptides
  • Mechanism of Action Activating transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma; Neuroblastoma

Most Recent Events

  • 12 Jul 2016 Preclinical trials in Neuroblastoma in USA (unspecified route)
  • 12 Jul 2016 Preclinical trials in Glioblastoma in USA (unspecified route)
  • 12 Jul 2016 Sapience Therapeutics in-licenses ST 36 from Columbia University
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top